<?xml version="1.0" encoding="UTF-8"?>
<p>Included participants were aged ≥18 years at the time of informed consent. Participants had to present with active DLE or SCLE skin disease (with or without systemic manifestations of SLE).
 <xref rid="R42" ref-type="bibr">42 43</xref> Concomitant antimalarial or systemic immunosuppressive therapies were allowed if doses were stable for ≥28 days before the day 1 visit. Prednisone or equivalent maximum dosage was 15 mg/day. High-potency topical steroids and/or other topical agents had to be stopped 7 days before the day 1 visit. HVs had to be in good overall health as determined by the investigator. For further details, see inclusion and exclusion criteria in online supplementary materials.
</p>
